¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

´ëÇÑ°£¾ÏÇÐȸ APPLE 2023 (The 13th Asia-Pacific Primary Liver Cancer Expert Meeting) - Day3 : 2023-07-08

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 

´ëÇÑ°£¾ÏÇÐȸ APPLE 2023 (The 13th Asia-Pacific Primary Liver Cancer Expert Meeting) - Day3 : 2023-07-08
±³À°ÀÏÀÚ : 2023-07-08
±³À°Àå¼Ò : ±×·£µå ÀÎÅÍÄÁƼ³ÙÅ» ¼­¿ï Æĸ£³ª½º 5F Room 1 ¿Ü 1°³·ë

±³À°ÁÖÁ¦ : APPLE 2023 (The 13th Asia-Pacific Primary Liver Cancer Expert Meeting) - Day3

ÁÖÃÖ±â°ü : ´ëÇÑ°£¾ÏÇÐȸ
´ã´çÀÚ : Ȳ¼öÁ¤
¿¬¶ôó : 02-373-1005  

À̸ÞÀÏ : apple2023@hbni.co.kr

±³À°Á¾·ù : ³»°ú, ¿Ü°ú, ¿µ»óÀÇÇаú, ¹æ»ç¼±Á¾¾çÇаú, º´¸®°ú

Âü¼®¿¹»óÀÎ : 700¸í
Èñ¸ÁÆòÁ¡ : 6Á¡

Áö¿ª : ¼­¿ïƯº°½Ã
±³À°½Ã°£ : 13 ½Ã°£ 20ºÐ

¼¼ºÎ¼ö°­·á : 0¿ø  

ºñ°í [Regular Registration-Non-Member Rate] Doctor, Healthcare Professionals: KRW 300,000 / USD 300 Fellow, Resident, Researcher, Others: KRW 250,000 / USD 250 Poster Presenter: KRW 100,000 / USD 100 [Regular Registration-Member Rate] Doctor, Healthcare Professionals: KRW 250,000 / USD 250 Fellow, Resident, Researcher, Others: KRW 200,000 / USD 200 Poster Presenter: KRW 100,000 / USD 100


±¸ºÐ ¿ùÀÏ °­ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ

±³À°½Ã°£ 07¿ù 08ÀÏ ÀÎÅÍÄÁƼ³ÙÅ» ¼­¿ï Æĸ£³ª½º 5F Room 1 08:30~08:50 Optimal First-Line Therapy for HCC Baek-Yeol Ryoo(Univ. of Ulsan)

±³À°½Ã°£ 07¿ù 08ÀÏ ÀÎÅÍÄÁƼ³ÙÅ» ¼­¿ï Æĸ£³ª½º 5F Room 1 08:50~09:10 Optimal Subsequent Option after First-Line Immuno-Oncology Therapy Andrew Zhu(I-Mab Biopharma, Shanghai)

±³À°½Ã°£ 07¿ù 08ÀÏ ÀÎÅÍÄÁƼ³ÙÅ» ¼­¿ï Æĸ£³ª½º 5F Room 1 09:10~09:30 Optimal Subsequent Option after First-Line Tyrosine Kinase Inhibitor Therapy Chih-Hung Hsu(National Taiwan Univ., Taipei)

±³À°½Ã°£ 07¿ù 08ÀÏ ÀÎÅÍÄÁƼ³ÙÅ» ¼­¿ï Æĸ£³ª½º 5F Room 1 09:30~09:50 Matching the Right Agents with the Right Patients for the Management of HCC: Biomarkers for Systemic Therapy Thomas Yau(The Univ. of Hong Kong, Hong Kong)

Åä·Ð 07¿ù 08ÀÏ ÀÎÅÍÄÁƼ³ÙÅ» ¼­¿ï Æĸ£³ª½º 5F Room 1 09:50~10:00 Discussion Baek-Yeol Ryoo, Andrew Zhu, Chih-Hung Hsu, Thomas Yau(Univ. of Ulsan, I-Mab Biopharma, Shanghai, National Taiwan Univ., Taipei, The Univ. of Hong Kong, Hong Kong)

±³À°½Ã°£ 07¿ù 08ÀÏ ÀÎÅÍÄÁƼ³ÙÅ» ¼­¿ï Æĸ£³ª½º 5F Room 1 10:20~11:00 Update on the Molecular-Pathological Features of HCC and Cholangiocarcinoma Young Nyun Park(Yonsei Univ.)

±³À°½Ã°£ 07¿ù 08ÀÏ ÀÎÅÍÄÁƼ³ÙÅ» ¼­¿ï Æĸ£³ª½º 5F Room 1 11:00~11:20 Trajectory of Immune Evolution and Mechanism of Response to Immunotherapy in Hepatocellular Carcinoma Valeri Chew (Duke-NUS Medical School, Singapore)

±³À°½Ã°£ 07¿ù 08ÀÏ ÀÎÅÍÄÁƼ³ÙÅ» ¼­¿ï Æĸ£³ª½º 5F Room 1 11:20~11:40 Rechallenging of Immuno-Oncology Treatment after Complications: Can It Be Done Safely? Stephen Lam Chan(The Chinese Univ. of Hong Kong, Hong Kong)

±³À°½Ã°£ 07¿ù 08ÀÏ ÀÎÅÍÄÁƼ³ÙÅ» ¼­¿ï Æĸ£³ª½º 5F Room 1 11:40~12:00 Neo-Adjuvant or Adjuvant Immunotherapy in HCC: Where Are We Now? Ann-Lii Cheng(National Taiwan Univ. Taipei)

±³À°½Ã°£ 07¿ù 08ÀÏ ÀÎÅÍÄÁƼ³ÙÅ» ¼­¿ï Æĸ£³ª½º 5F Room 1 12:00~12:20 Immuno-Oncology in the Treatment of HCC: Future Perspectives Richard Finn(Univ. of California Los Angeles, LA)

Åä·Ð 07¿ù 08ÀÏ ÀÎÅÍÄÁƼ³ÙÅ» ¼­¿ï Æĸ£³ª½º 5F Room 1 12:20~12:30 Discussion Valeri Chew, Stephen Lam Chan, Ann-Lii Cheng, Richard Finn(Duke-NUS Medical School, Singapore, The Chinese Univ. of Hong Kong, Hong Kong, National Taiwan Univ. Taipei, Univ. of California Los Angeles, LA)

±³À°½Ã°£ 07¿ù 08ÀÏ ÀÎÅÍÄÁƼ³ÙÅ» ¼­¿ï Æĸ£³ª½º 5F Room 1 13:30~13:50 Novel Targets in HCC Augusto Villanueva(Icahn School of Medicine at Mount Sinai, New York)

±³À°½Ã°£ 07¿ù 08ÀÏ ÀÎÅÍÄÁƼ³ÙÅ» ¼­¿ï Æĸ£³ª½º 5F Room 1 13:50~14:10 CAR T Cell Therapy in HCC: Prospects and Challenges Kyungho Choi(Seoul National Univ.)

±³À°½Ã°£ 07¿ù 08ÀÏ ÀÎÅÍÄÁƼ³ÙÅ» ¼­¿ï Æĸ£³ª½º 5F Room 1 14:10~14:30 Promising Agents in Early Clinical Trials for Liver Cancer Masafumi Ikeda(National Cancer Center Hospital East, Kashiwa)

±³À°½Ã°£ 07¿ù 08ÀÏ ÀÎÅÍÄÁƼ³ÙÅ» ¼­¿ï Æĸ£³ª½º 5F Room 1 14:30~14:50 Radiation Therapy in HCC: Future Perspectives Jinsil Seong(Yonsei Univ.)

Åä·Ð 07¿ù 08ÀÏ ÀÎÅÍÄÁƼ³ÙÅ» ¼­¿ï Æĸ£³ª½º 5F Room 1 14:50~15:00 Discussion Augusto Villanueva, Kyungho Choi, Masafumi Ikeda, Jinsil Seong(Icahn School of Medicine at Mount Sinai, New York, Seoul National Univ., National Cancer Center Hospital East, Kashiwa, Yonsei Univ.)

±³À°½Ã°£ 07¿ù 08ÀÏ ÀÎÅÍÄÁƼ³ÙÅ» ¼­¿ï Æĸ£³ª½º 5F Room 1 15:20~15:40 Pathological and Molecular Features of Intrahepatic Cholangiocarcinoma Peter Schirmacher(Universität Heidelberg, Heidelberg)

±³À°½Ã°£ 07¿ù 08ÀÏ ÀÎÅÍÄÁƼ³ÙÅ» ¼­¿ï Æĸ£³ª½º 5F Room 1 15:40~16:00 Surgical Management of Intrahepatic Cholangiocarcinoma: Comparison with HCC Etsuro Hatano(Kyoto Univ., Kyoto)

±³À°½Ã°£ 07¿ù 08ÀÏ ÀÎÅÍÄÁƼ³ÙÅ» ¼­¿ï Æĸ£³ª½º 5F Room 1 16:00~16:20 Systemic Therapy for Intrahepatic Cholangiocarcinoma: Current and Future Perspectives Do-Youn Oh(Seoul National Univ.)

±³À°½Ã°£ 07¿ù 08ÀÏ ÀÎÅÍÄÁƼ³ÙÅ» ¼­¿ï Æĸ£³ª½º 5F Room 1 16:20~16:40 Radiation Therapy for Intrahepatic Cholangiocarcinoma Christopher Crane(Weill Cornell College at Cornell Univ., New York)

Åä·Ð 07¿ù 08ÀÏ ÀÎÅÍÄÁƼ³ÙÅ» ¼­¿ï Æĸ£³ª½º 5F Room 1 16:40~16:50 Discussion Peter Schirmacher, Etsuro Hatano, Do-Youn Oh, Christopher Crane(Universität Heidelberg, Heidelberg, Kyoto Univ., Kyoto, Seoul National Univ., Weill Cornell College at Cornell Univ., New York)

±³À°½Ã°£ 07¿ù 08ÀÏ ÀÎÅÍÄÁƼ³ÙÅ» ¼­¿ï Æĸ£³ª½º 5F Room 2 08:30~08:50 AI-Based Cancer Screening Using Liquid Biopsy Eun-Hae Cho(GC Genome)

±³À°½Ã°£ 07¿ù 08ÀÏ ÀÎÅÍÄÁƼ³ÙÅ» ¼­¿ï Æĸ£³ª½º 5F Room 2 08:50~09:10 Qualitative and Quantitative Imaging Biomarkers to Predict Prognosis of HCC Seung Soo Lee (Univ. of Ulsan)

±³À°½Ã°£ 07¿ù 08ÀÏ ÀÎÅÍÄÁƼ³ÙÅ» ¼­¿ï Æĸ£³ª½º 5F Room 2 09:10~09:30 AI based pathology: a new generation of biomarkers for hepatocellular carcinoma Julien Calderaro(Université Paris-Est Créteil, Créteil)

±³À°½Ã°£ 07¿ù 08ÀÏ ÀÎÅÍÄÁƼ³ÙÅ» ¼­¿ï Æĸ£³ª½º 5F Room 2 09:30~09:50 Predicting HCC Risk Using Artificial Intelligence Jeong-Hoon Lee(Seoul National Univ.)

Åä·Ð 07¿ù 08ÀÏ ÀÎÅÍÄÁƼ³ÙÅ» ¼­¿ï Æĸ£³ª½º 5F Room 2 09:50~10:00 Discussion Eun-Hae Cho, Seung Soo Lee, Julien Calderaro, Jeong-Hoon Lee(GC Genome, Univ. of Ulsan, Université Paris-Est Créteil, Créteil, Seoul National Univ.)

±³À°½Ã°£ 07¿ù 08ÀÏ ÀÎÅÍÄÁƼ³ÙÅ» ¼­¿ï Æĸ£³ª½º 5F Room 2 10:20~11:00 Update on the Molecular-Pathological Features of HCC and Cholangiocarcinoma Young Nyun Park(Yonsei Univ.)

±³À°½Ã°£ 07¿ù 08ÀÏ ÀÎÅÍÄÁƼ³ÙÅ» ¼­¿ï Æĸ£³ª½º 5F Room 2 11:00~11:20 Extended Criteria for Liver Transplantation in HCC Toru Ikegami(Kyushu Univ., Fukuoka)

±³À°½Ã°£ 07¿ù 08ÀÏ ÀÎÅÍÄÁƼ³ÙÅ» ¼­¿ï Æĸ£³ª½º 5F Room 2 11:20~11:40 Down-Staging and Waiting Times for Liver Transplantation in Advanced HCC Dong Jin Joo(Yonsei Univ.)

±³À°½Ã°£ 07¿ù 08ÀÏ ÀÎÅÍÄÁƼ³ÙÅ» ¼­¿ï Æĸ£³ª½º 5F Room 2 11:40~12:00 Role of Transplantation in Combined Hepatocellular-Cholangiocarcinoma Linda Wong(Univ. of Hawaii, Honolulu)

±³À°½Ã°£ 07¿ù 08ÀÏ ÀÎÅÍÄÁƼ³ÙÅ» ¼­¿ï Æĸ£³ª½º 5F Room 2 12:00~12:20 Multidisciplinary Approach for Post-Liver Transplantation Recurrence Kenneth Siu Ho Chok(The Univ. of Hong Kong, Hong Kong)

Åä·Ð 07¿ù 08ÀÏ ÀÎÅÍÄÁƼ³ÙÅ» ¼­¿ï Æĸ£³ª½º 5F Room 2 12:20~12:30 Discussion Toru Ikegami, Dong Jin Joo, Linda Wong, Kenneth Siu Ho Chok(Kyushu Univ., Fukuoka, Yonsei Univ., Univ. of Hawaii, Honolulu, The Univ. of Hong Kong, Hong Kong)

±³À°½Ã°£ 07¿ù 08ÀÏ ÀÎÅÍÄÁƼ³ÙÅ» ¼­¿ï Æĸ£³ª½º 5F Room 2 13:30~13:50 Associating Liver Partition and Portal Vein Ligation for Staged Hepatectomy (ALPPS) for Unresectable HCC Jian Zhou(Fudan Univ., Shanghai)

±³À°½Ã°£ 07¿ù 08ÀÏ ÀÎÅÍÄÁƼ³ÙÅ» ¼­¿ï Æĸ£³ª½º 5F Room 2 13:50~14:10 Liver Resection for Multiple HCC Shin Hwang(Univ. of Ulsan)

±³À°½Ã°£ 07¿ù 08ÀÏ ÀÎÅÍÄÁƼ³ÙÅ» ¼­¿ï Æĸ£³ª½º 5F Room 2 14:10~14:30 Surgical Resection for Intrahepatic and Extrahepatic Recurrent HCC Etsuro Hatano(Kyoto Univ., Kyoto)

±³À°½Ã°£ 07¿ù 08ÀÏ ÀÎÅÍÄÁƼ³ÙÅ» ¼­¿ï Æĸ£³ª½º 5F Room 2 14:30~14:50 Laparoscopic Repeated Liver Resection for Recurrent HCC Zenichi Morise(Fujita Health Univ., Toyoake)

Åä·Ð 07¿ù 08ÀÏ ÀÎÅÍÄÁƼ³ÙÅ» ¼­¿ï Æĸ£³ª½º 5F Room 2 14:50~15:00 Discussion Jian Zhou, Shin Hwang, Etsuro Hatano, Zenichi Morise(Fudan Univ., Shanghai, Univ. of Ulsan, Kyoto Univ., Kyoto, Fujita Health Univ., Toyoake)

±³À°½Ã°£ 07¿ù 08ÀÏ ÀÎÅÍÄÁƼ³ÙÅ» ¼­¿ï Æĸ£³ª½º 5F Room 2 15:20~15:40 Morphological Classification of HCC and Potential Clinical Implications Haeryoung Kim(Seoul National Univ.)

±³À°½Ã°£ 07¿ù 08ÀÏ ÀÎÅÍÄÁƼ³ÙÅ» ¼­¿ï Æĸ£³ª½º 5F Room 2 15:40~16:00 Stratification of HCC : Cellular, Molecular and Blood-Based Biomarkers Irene Ng(The Univ. of Hong Kong, Hong Kong)

±³À°½Ã°£ 07¿ù 08ÀÏ ÀÎÅÍÄÁƼ³ÙÅ» ¼­¿ï Æĸ£³ª½º 5F Room 2 16:00~16:20 Correlation of Imaging and Molecular-Pathologic Subtypes of HCC Jin-Young Choi(Yonsei Univ.)

±³À°½Ã°£ 07¿ù 08ÀÏ ÀÎÅÍÄÁƼ³ÙÅ» ¼­¿ï Æĸ£³ª½º 5F Room 2 16:20~16:40 Biopsy for HCC: Tissue or Liquid? Xin-Rong Yang(Fudan Univ, Shanghai)

Åä·Ð 07¿ù 08ÀÏ ÀÎÅÍÄÁƼ³ÙÅ» ¼­¿ï Æĸ£³ª½º 5F Room 2 16:40~16:50 Discussion Haeryoung Kim, Irene Ng, Jin-Young Choi, Xin-Rong Yang(Seoul National Univ., The Univ. of Hong Kong, Hong Kong, Yonsei Univ., Fudan Univ, Shanghai)

 

ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" ´ëÇÑ°£¾ÏÇÐȸ APPLE 2023 (The 13th Asia-Pacific Primary Liver Cancer Expert Meeting) - Day3 : 2023-07-08""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û (¿Â¶óÀÎ) ´ëÇѼ¼Æ÷º´¸®ÇÐȸ Á¦31Â÷ º´¸®Àǻ縦 À§ÇÑ ¼¼Æ÷º´¸®±³À° 4Â÷ : 2023-07-08
´ÙÀ½±Û ¼­¿ï¾Æ»êº´¿ø A FLIGHT symposium 2023 : 2023-07-08
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
20925 ÀüºÏ Á¦ 53Â÷ ´ëÇѳëÀκ´ÇÐȸ È£³²Áöȸ ÇмúÁý´äȸ : 2024-07-27 0 44 2024-05-28
20924 ¼­¿ï 2024 Á¦27ȸ ´ëÇѾȸ鼺ÇüÀç°ÇÇÐȸ Ãá°è Çмú´ëȸ : 2024-07-21 0 40 2024-05-28
20923 °æ±â 2024³â ÀÏ»ê¹éº´¿ø Á¤Çü¿Ü°ú ½ÉÆ÷Áö¾ö : 2024-07-21 0 34 2024-05-28
20922 ¼­¿ï 2024³â ü°èÀû ¹®Çå°íÂû(¸ÞŸºÐ¼®) ³í¹®Ãâ°£ ¿öÅ©¼¥ 2Â÷(2ÀÏÂ÷) : 2024-07-20 0 39 2024-05-28
20921 ¼­¿ï Á¦33Â÷ ´ç´¢º´ ¿¬±¸ ÇÏ°è¿öÅ©¼¥ : 2024-07-20 0 34 2024-05-28
20920 ¼­¿ï ´ëÇÑÁ¾¾ç³»°úÇÐȸ Recent updates in GU Cancers 2024 : 2024-07-19 0 67 2024-05-28
20919 ¼­¿ï 2024³â ü°èÀû ¹®Çå°íÂû(¸ÞŸºÐ¼®) ³í¹®Ãâ°£ ¿öÅ©¼¥ 2Â÷(1ÀÏÂ÷) : 2024-07-19 0 22 2024-05-28
20918 ¼­¿ï [¿Â¶óÀÎ] Áø´Ü¿ë ¹æ»ç¼± ¾ÈÀü°ü¸®Ã¥ÀÓÀÚ ¼±ÀÓ±³À° : 2024-07-14 0 33 2024-05-28
20917 °æºÏ 2024³â ´ëÇÑ°ñ´Ù°øÁõÇÐȸ ¿µ³² ¿¬¼ö°­Á : 2024-07-14 0 31 2024-05-28
20916 °æ±â ÀÎÁ¦´ëÇб³ ÀÏ»ê¹éº´¿ø ¼ÒÈ­±â³»°ú °³¿øÀÇ ¿¬¼ö°­Á : 2024-07-13 0 35 2024-05-28
20915 °æ±â 2024³â ÀÇÁ¤ºÎÀ»Áö´ëÇб³º´¿ø Á¦1ȸ ½Å°æ°ú °³¿øÀÇ ¿¬¼ö±³À° : 2024-07-13 0 30 2024-05-28
20914 ºÎ»ê Á¦6ȸ ºÎ»ê¼º¸ðº´¿ø ¼Ò¾Æû¼Ò³â°ú ½ÉÆ÷Áö¾ö : 2024-07-13 0 27 2024-05-28
20913 ¼­¿ï 2024 ´ëÇѽŰ泻ºÐºñ¿¬±¸È¸ ¿¬¼ö°­Á : 2024-07-13 0 31 2024-05-28
20912 ¼­¿ï ÀºÆò±¸ÀÇ»çȸ Á¦3Â÷¿¬¼ö±³À° : 2024-07-11 0 33 2024-05-28
20911 ¼­¿ï (¿Â¶óÀÎ) 2024³â ¼Ò¾Æ½ÅÀå Post-graduate education course : 2024-07-08 0 37 2024-05-28
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷